James Pauff

James Pauff has a diverse work experience in the field of oncology. James is currently working at Loxo Oncology at Lilly as an Associate Vice President in Clinical Development, where they have been since January 2023. Prior to this, they held the role of Medical Director at the same company since January 2021.

Before their time at Loxo Oncology, James worked as an Investigator in the Drug Development Unit at Sarah Cannon Research Institute from March 2020 to February 2021. James also served as a Medical Oncologist at Tennessee Oncology during the same period.

From 2016 to 2020, James worked at AbbVie, first as an Associate Medical Director from July 2016 to May 2018, and then as an Associate Medical Director from May 2018 to April 2020.

Earlier in their career, James served as a Staff Physician in Medical Oncology at Froedtert South from 2018 to 2020.

James has also contributed to research and clinical practice at Vanderbilt University Medical Center. James completed a Clinical Fellowship in Medical Oncology from 2011 to 2016, where their research focused on resistance mechanisms in ER+ breast cancer. James also worked as a Resident Physician at the same institute from 2011 to 2013.

Additionally, James has held positions as a Medical Advisor at MetaMed Research, Inc. from 2013 to 2015, as a Board of Directors member at the American Physician Scientists Association from 2008 to 2011, and as a Graduate Fellow at The Ohio State University from 2004 to 2011. James was a member of the Board of Advisors at AAAS from 2008 to 2009.

James Pauff earned a Bachelor of Science (B.S.) degree in Chemistry, Biochemistry, and Zoology from Miami University in 2004. James then pursued a Doctor of Philosophy (PhD) degree in Biochemistry from The Ohio State University, which they completed in 2008. Following that, James obtained a Doctor of Medicine (MD) degree from The Ohio State University in 2011. James has also obtained additional certifications in Medical Oncology and Internal Medicine from the American Board of Internal Medicine in 2016 and 2015 respectively.